natgillin/translations-raw huggingface dataset:
Based on these pharmacokinetic results, when used in children with PAH 1 year and older, the recommended starting and maintenance dose is 2 mg/kg morning and evening.
Nende farmakokineetiliste tulemuste põhjal on ravimi kasutamisel pulmonaalse arteriaalse hüpertensiooniga 1-aastastel ja vanematel lastel soovitatav algannus ja säilitusannus 2 mg/kg hommikul ja õhtul.
Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic medicinal products: carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide.
Nende ühendatud andmete põhjal ei avaldanud retigabiin kliiniliselt olulist toimet järgmiste epilepsiavastaste ravimite minimaalsele plasmakontsentratsioonile: karbamasepiin, klobasaam, klonasepaam, gabapentiin, lamotrigiin, levetiratsetaam, okskarbasepiin, fenobarbitaal, fenütoiin, pregabaliin, topiramaat, valproaat, zonisamiid.
Based on these results vardenafil 10 mg orodispersible tablets can be taken with or without food.
Nende tulemuste kohaselt võib vardenafiili suus dispergeeruvaid tablette võtta koos toiduga või ilma.
Based on these results, a positive benefit-risk of bosutinib in patients with previously untreated CML in the chronic phase has not been established.
Nende tulemuste alusel ei ole varem KML-i kroonilises faasis mitte ravitud patsientidel bosutiniibi positiivset kasu-riski suhet tõestatud.
Based on these results, no dose adjustment for paracetamol is required but the delayed tmax observed when paracetamol is administered 1-4 hours after lixisenatide should be taken into account when a rapid onset of action is required for efficacy..
Nende tulemuste põhjal ei ole paratsetamooli annuse kohandamine vajalik, kuid paratsetamooli manustamisel 1...4 tundi pärast liksisenatiidi on täheldatud tmax hilinemist, millega peab arvestama, kui on vajalik toime kiire algus.
Based on these results, no dose adjustment for warfarin is required when co-administered with lixisenatide; however, frequent monitoring of INR in patients on warfarin and/or coumarin derivatives is recommended at the time of initiation or ending of lixisenatide treatment.
Nende andmete põhjal ei ole varfariini annuse kohandamine samaaegsel manustamisel liksisenatiidiga vajalik, kuid varfariiniga ja/või kumariini derivaatidega ravitavatel patsientidel on soovitatav sageli kontollida INR-i, kui alustatakse või lõpetatakse ravi liksisenatiidiga
Based on these results, no dose adjustment for warfarin is required when co-administered with lixisenatide; however, frequent monitoring of INR in patients on warfarin and/or coumarin derivatives is recommended at the time of initiation or ending of lixisenatide treatment.
Nende andmete põhjal ei ole varfariini annuse kohandamine samaaegsel manustamisel liksisenatiidiga vajalik, kuid varfariiniga ja/või kumariini derivaatidega ravitavatel patsientidel on soovitatav sageli kontollida INR-i, kui alustatakse või lõpetatakse ravi liksisenatiidiga.
Based on these risk factors, prevention of osteoporosis with Evista is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures.
Nende riskifaktorite põhjal on osteoporoosi vältimine Evista’ga näidustatud naistele kümne aasta jooksul pärast menopausi, kui selgroo LMT on 1,0 kuni 2,5 SD alla normaalse noore populatsiooni keskmist väärtust, võttes arvesse nende kõrget eluaegset ohtu osteoporootilisteks murdudeks.
Based on these risk factors, prevention of osteoporosis with Optruma is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures.
Nende riskifaktorite põhjal on osteoporoosi vältimine Optruma’ga näidustatud naistele kümne aasta jooksul pärast menopausi, kui selgroo LMT on 1,0 kuni 2,5 SD alla normaalse noore populatsiooni keskmist väärtust, võttes arvesse nende kõrget eluaegset ohtu osteoporootilisteks murdudeks.
Based on these study results, both methods of daptomycin administration, the 2-minute intravenous injection and the 30-minute intravenous infusion, had a similar safety and tolerability profile.
Nende uuringute tulemuste põhjal on daptomütsiini mõlemad manustamisviisid – 2 minutit kestev intravenoossne süst ja 30 minutit kestev intravenoossne infusioon – sarnase ohutuse ja talutavusega.
Based on these trial results, INTELENCE is not recommended for use in combination with N(t)RTIs only in patients who have experienced virological failure on an NNRTI- and N(t)RTI-containing regimen.
Nendele uuringutulemustele tuginedes ei soovitata INTELENCE’i kasutada kombinatsioonis N(t)RTIdega ainult patsientidel, kellel puhul NNRTId ja N(t)RTId sisaldava raviskeemi viroloogiline vastus oli ebapiisav.
Based on this and all other available data, the Committee decided that Metalyse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Sellest ja olemasolevatest andmetest lähtudes otsustas komitee, et Metalyse kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
Based on this limited experience the safety profile of Odefsey in patients with HIV/HBV co-infection appears to be similar to that in patients with HIV-1 monoinfection.
Selle piiratud kogemuse põhjal näib Odefsey ohutusprofiil HBV-ga nakatunud HIV patsientidel sarnanevat ainult HIV-1-infektsiooniga patsientide omaga.
Based on this limited experience, the safety profile of Descovy in patients with HIV/HBV co-infection appears to be similar to that in patients with HIV-1 monoinfection (see section 4.4).
Selle piiratud kogemuse põhjal näib Descovy ohutusprofiil HBV-ga nakatunud HIV patsientidel sarnanevat ainult HIV-1-infektsiooniga patsientide omaga (vt lõik 4.4).
Based on this limited experience, the safety profile of Genvoya in patients with HIV/HBV co-infection appears to be similar to that in patients with HIV-1 monoinfection.
Selle piiratud kogemuse põhjal näib Genvoya ohutusprofiil HBV-ga nakatunud HIV patsientidel sarnanevat ainult HIV-1-infektsiooniga patsientide omaga.
Based on this pharmacokinetic study, ambrisentan would not be expected to significantly affect exposure to oestrogen- or progestogen- based contraceptives.
Selle farmakokineetika uuringu põhjal ei tohiks ambrisentaan oluliselt mõjutada östrogeeni või progestogeeni sisaldavate kontratseptiivide ekspositsiooni.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abilify, including the appropriate precautions to be followed by healthcare professionals and patients.
Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Abilify ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abseamed, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Abseamedi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adempas, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Adempase omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Anoro, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Anoro omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Arzerra, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Arzerra omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Atriance, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Atriance omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Avastin, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Avastini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bexsero, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Bexsero omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Binocrit, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Binocriti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Blincyto, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Blincyto omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bortezomib Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Bortezomib Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bosulif, including the appropriate precautions to be followed by healthcare professionals and patients.
Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Bosulifi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Briviact, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Briviacti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Budesonide/Formoterol Teva Pharma B.V., including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi Budesonide/Formoterol Teva Pharma B.V. omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bydureon, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Budyreoni omaduste kokkuvõttesse ja pakendi infolehele ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Celvapan, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Celvapani omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ceplene, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Ceplene omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cerdelga, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Cerdelga omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cimzia, including the appropriate precautions to be followed by healthcare professionals and patients.
Kavast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Cimzia ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Clopidogrel ratiopharm, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Clopidogrel ratiopharmi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Coagadex, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Coagadexi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Corlentor, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Corlentori omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cubicin, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Cubicini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cyramza, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Cyramza omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Darzalex, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Darzalexi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Defitelio, including the appropriate precautions to be followed by healthcare professionals and patients.
Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Defitelio ohutusteave, sealhulgas tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Deltyba, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Deltyba omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ebilfumin, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Ebilfumini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ebymect, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Ebymecti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Edistride, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Edistride omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eliquis, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Eliquise omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Elocta, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Elocta omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Elonva, including the appropriate precautions to be followed by healthcare professionals and patients.
Kavast lähtudes lisati Elonva omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Empliciti, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Empliciti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Epoetin Alfa Hexal, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Epoetin Alfa Hexali ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Esbriet, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Esbrieti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Esmya, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Esmya omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Exjade, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Exjade omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Exviera, including information on the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Exviera omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eylea, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Eylea omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Feraccru, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Feraccru omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Fexeric, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Fexerici omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Foclivia, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Foclivia ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Genvoya, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Genvoya omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.